Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

Hematology, oncology > heme 2 > Flashcards

heme 2 Flashcards

1
Q

Percent saturation

A

transferrin saturation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

percent saturation calculation

A

serum iron divided by the total iron-binding capacity of the available transferrin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

POD meaning

A

progression of disease

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

anticoagulants that will prolong PTT

A

Heparin, dabigatran, argatroban, direct factor Xa inhibitors (variable)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the direct factor Xa inhibitors

A

Apixaban, edoxaban, and rivaroxaban

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

NOACs approved for VTE

A

apixaban, dabigatran, edoxaban and rivaroxaban

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

elimination half life of most NOACs

A

12 hours

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

NOAC that must be taken with food

A

rivoraxaban (xarelto)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

NOACs with liver metabolism

A

eiliquis, xarelto

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

NOACs affecting PTT

A

dabigatran, Xa inhibitors

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

triple antithrombotic therapy means

A

Dual antiplatelet therapy + oral anticoagulation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

anyone on triple therapy should be on a

A

PPI

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Novel P2Y12 receptor inhibitors

A

prasugrel, ticagrelor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

management of NOAC overdose?

A

activated charcoal (if OD within 2h)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

NOAC with dominant renal excretion

A

dabigatran

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Perioperative management of NOACs

A

Depends on bleeding risk
Minor bleeding risk –> European guidelines say discontinued 24h before
Higher bleeding risk –> stop 48h before sugery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

long acting derivative of fondaparinux

A

idraparinux

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

agents that cause HIT

A

UFH and LMWH, not fondaparinux

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

fondaparinux trade name

A

arixtra

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

fondaparinux mechanism

A

synthetic pentasaccharide factor Xa inhibitor. Fondaparinux binds antithrombin and accelerates its inhibition of factor Xa.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

what is alloimmunization

A

An immune response to foreign antigens after exposure to genetically different cells or tissues.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

RCE means

A

red cell exchange transfusion

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

what are the thrombopoietin receptor agonists (TPO-RA)?

A

eltrombopag or romiplostim

24
Q

what is microangiopathic hemolytic anemia (MAHA) defined as?

A

Descriptive term for non-immune hemolysis (ie, Coombs-negative hemolysis) resulting from intravascular red blood cell fragmentation that produces schistocytes on the peripheral blood smear (picture 1) [1]. Abnormalities in the microvasculature, including small arterioles and capillaries, are frequently involved. However, intravascular devices such as a prosthetic heart valve or assist devices may also cause MAHA.

25
Q

what is TMA physiologically?

A

Defined specific pathologic lesion in which abnormalities in the vessel wall of arterioles and capillaries lead to microvascular thrombosis. Pathologically defined, but commonly clinically inferred. Includes TTP and HUS.

26
Q

definition of neutropenia and severe neutropenia

A

neutropenia = ANC <1500

severe neutropenia = ANC <500

27
Q

what is Evans syndrome?

A
  • very rare autoimmune disease causing autoimmune thrombocytopenia and hemolytic anemia
28
Q

treatment of iron overload syndrome

A

IF HgB okay → phlebotomy
IF anemic → Deferasirox PO or deferoxamine (only IV) + council on GI side effects
IF SCD → exchange transfusion

29
Q

types of stem cell transplants

A

High intensity (myeloablative) and low intensity

30
Q

myeloablative HSCT

A

Myeloablative (high-intensity) stem cell transplant uses high doses of chemotherapy and may use radiation therapy to destroy cancer cells. In this process, bone marrow/stem cells are also destroyed. Patients receive an infusion of new stem cells to rebuild blood and the immune system.

31
Q

clinical features of pure red cell aplasia

A

Isolated anemia + SCD patient + low reticulocyte response + no retics in bone marrow

32
Q

what is the function of tranexamic acid?

A

antifibrinolytic agent

33
Q

management of bleeding patient with supratherapeutic INR

A

1) Vitamin K IV 10 mg, slow infusion, repeat q12h if warfarin persistently supratherapeutic
2) 4 Factor-prothrombin complex concentrate, dosing – (table 3
Recheck PT/INR 30 minutes after

34
Q

why vitamin K should be given PO rather than IV

A

small risk of anaphylaxis, especially when given rapidly

35
Q

when do you treat iron overload?

A

ferritin >1000

36
Q

IDA diagnosis

A

IF noninflammatory state –>
Ferritin <20 OR <41 ng/mL in a patient with anemia and comorbidities = IDA by definition
High ferritin can’t be used to rule out because can be independently elevated. Ferritin >100 makes IDA unlikely.
TIBC → 16% = cutoff for IDA
IF inflammatory state →
***soluble transferrin receptor (measures level of transferrin in blood, which isn’t sensitive to inflammation)

37
Q

etiology of upper extremity DVTs

A

The majority (70 to 80 percent) of thrombotic events occurring in the superficial and deep veins of the upper extremity are due to intravenous catheters. The remainder are due to mechanical compression from anatomic abnormalities (eg, venous thoracic outlet syndrome)

38
Q

sequela of upper extremity DVT

A

embolism is less common compared with lower extremity DVT due to differences in epidemiology and risk factors [14]. (See ‘Epidemiology and risk factors’ above.)

Nevertheless, venous thromboembolism is still a serious problem.

39
Q

anticoagulation for upper extremity DVT

A

We suggest initial therapy with parenteral anticoagulants (low-molecular-weight heparin [LMWH], fondaparinux, unfractionated heparin) followed by a vitamin K antagonist (eg, warfarin) or LMWH. Sufficient data are lacking to recommend the use of a direct oral anticoagulant (DOAC) for the management of the acute phase of catheter-related upper extremity DVT.

40
Q

what are the deep veins of the upper extremity?

A

paired radial veins, paired ulnar veins, paired brachial veins, axillary vein, and subclavian vein

41
Q

Thalassemia lab profile

A

MCV very low + target cells, mildly elevated ferritin + normal red cell distribution width + normal RBC count or increased

42
Q

polycythemia definition

A

Increased hemoglobin: >16.5 g/dL (10.3 mmol/L) in men or >16.0 g/dL (10.0 mmol/L) in women
Increased hematocrit: >49 percent in men or >48 percent in women

43
Q

Relative polycythemia definition

A

Elevation of Hb and/or Hct due to a decrease in plasma volume alone (ie, without an increase of the RBC mass)

44
Q

leading cause of cancer-related death among men and women

A

lung cancer

45
Q

Normal hematocrit in men and women

A

Normal levels of hematocrit for men range from 41% to 50%. Normal level for women is 36% to 48%.

46
Q

why does warfarin require bridging?

A

1) In the initial period of starting warfarin a paradoxically increased state of coagulation exists and without bridging the patient is at risk of worsening of the clot.
2) Due to warfarin’s mechanism of action and the long half-life of some coagulation factors, the effects of warfarin to provide a therapeutic level of anticoagulation do not occur immediately.

47
Q

Do DOAC’s require bridging?

A

A study that evaluated an unfractionated heparin pharmacy dosing protocol for the treatment of VTE found that the average time to the first therapeutic lab value was 15 hours. This is also well beyond the time where a DOAC would reach a therapeutic level.

48
Q

Difference in gender in cancer death rates in the US

A

Cancer death rates are higher among males than females, although this gap has narrowed over time.

49
Q

3 highest incident cancer types in men

A

prostate, lung, crc

50
Q

3 highest incident cancer types in women

A

breast, lung, crc

51
Q

DIC labs

A
  • mild thrombocytopenia + low fibrinogen + elevated d-dimer + prolonged PT + PTT
  • think of it physiologically: dysfunction of fibrinolysis and activation of clotting cascade so you have low fibrinogen and consumption of clotting factors, leading to prolonged PT/PTT
52
Q

rare causes of microcytic anemia

A

lead poisoning, copper or zinc deficiency, some forms of drug-induced anemia, inherited syndromes of defective iron metabolism
sideroblastic anemia → alcohol, INH, lead exposure
hemolysis →

53
Q

correlation of fibrinogen level to DIC

A

Fibrinogen level was initially thought to be useful in the diagnosis of DIC but because it is an acute phase reactant, it will be elevated due to the underlying inflammatory condition. Therefore, a normal (or even elevated) level can occur in over 57% of cases. A low level, however, is more consistent with the consumptive process of DIC.

54
Q

Dabigatran reversal agent

A

idarucizumab (Praxbind, Boehringer Ingelheim)

55
Q

Eliquis reversal agent

A

andexanet alfa (AndexXa)

Hematology, oncology (218 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2024 Bold Learning Solutions. Terms and Conditions